Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 7:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 167 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Amantadine Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease

NCT00933608
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
memantine, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
55 Years to 90 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2014 · Synced Oct 2, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

Memantine Treatment Study of Pathological Gambling

NCT00585169
View directory record Official record
Conditions
Pathological Gambling
Interventions
Memantine Hydrochloride
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
New Haven, Connecticut • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Oct 2, 2026, 7:32 AM EDT
Terminated Not applicable Interventional Results available

Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease

NCT00794313
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Amantadine 300 mg, Topiramate, Sugar Pill
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 1, 2018 · Synced Oct 2, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

Memantine and Naltrexone Treatment for Opioid Dependence

NCT00125515
View directory record Official record
Conditions
Opioid Dependence
Interventions
Memantine, Naltrexone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 2, 2026, 7:32 AM EDT
Completed Phase 4 Interventional Results available

Memantine Treatment for Improving Rehabilitation Outcomes and Preventing Depression in Older Adults

NCT00183729
View directory record Official record
Conditions
Depression
Interventions
Memantine, Placebo
Drug · Other
Lead sponsor
Eric Lenze
Other
Eligibility
60 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 2, 2026, 7:32 AM EDT
Completed Phase 4 Interventional Results available

Memantine Augmentation of Lamotrigine Incomplete-Response in Bipolar Depression

NCT00305578
View directory record Official record
Conditions
Bipolar Depression
Interventions
Memantine, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Oct 2, 2026, 7:32 AM EDT
Recruiting Phase 2 Interventional

NTS-WBRT in Brain Metastases

NCT05013892
View directory record Official record
Conditions
Brain Metastases
Interventions
NTS-WBRT (normal tissue sparing whole brain radiation therapy), Memantine
Radiation · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 2, 2026, 7:32 AM EDT
Terminated Phase 2 Interventional Results available

Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease

NCT01789047
View directory record Official record
Conditions
Idiopathic Parkinson's Disease, Drug Induced Dyskinesia
Interventions
Topiramate, Placebo, Amantadine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
30 Years to 90 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 2, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

NCT01592786
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Interventions
Memantine Hydrochloride (HCl)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 12 Years
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
72
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Oct 2, 2026, 7:32 AM EDT
Completed Phase 1 Interventional

Study of Amantadine for Weight Stabilization During Olanzapine Treatment

NCT00287352
View directory record Official record
Conditions
Psychotic Disorder, Schizophreniform Disorder, Schizophrenia, Schizoaffective Disorder, Mood Disorders With Psychotic Features
Interventions
Olanzapine, Amantadine, Olanzapine and placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 2, 2011 · Synced Oct 2, 2026, 7:32 AM EDT
Active, not recruiting Phase 2 Interventional

Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge

NCT05418049
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Baclofen, Memantine, Roflumilast, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 2, 2026, 7:32 AM EDT
Completed Phase 3 Interventional

Clinical Trial of Memantine for Major Depression

NCT00040261
View directory record Official record
Conditions
Depression
Interventions
Memantine HCL
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 2, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking

NCT01535040
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Tobacco Use Disorder
Interventions
memantine hydrochloride, placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 2, 2026, 7:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Pilot Clinical Trial Of Memantine for Essential Tremor

NCT00439699
View directory record Official record
Conditions
Essential Tremor
Interventions
Memantine
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 2, 2026, 7:32 AM EDT
Completed Not applicable Interventional Results available

Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression

NCT00186498
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
memantine, Placebo Oral Capsule
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 2, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

Memantine Treatment of Compulsive Buying

NCT00830375
View directory record Official record
Conditions
Compulsive Buying
Interventions
Memantine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 2, 2026, 7:32 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID

NCT02153632
View directory record Official record
Conditions
Parkinson's Disease, Levodopa Induced Dyskinesia (LID)
Interventions
amantadine HCl ER, Placebo
Drug
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Tucson, Arizona • Fountain Valley, California • Irvine, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 2, 2026, 7:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treatment With Namenda in Women at Risk for Cognitive Decline

NCT00242632
View directory record Official record
Conditions
Dementia
Interventions
Namenda
Drug
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 2, 2026, 7:32 AM EDT
Completed Phase 3 Interventional Results available

Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors

NCT00566852
View directory record Official record
Conditions
Cognitive/Functional Effects, Metastatic Cancer, Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Memantine, Placebo, Whole brain radiation therapy
Drug · Other · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
229
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 183 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 2, 2026, 7:32 AM EDT
Terminated Phase 3 Interventional

Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions

NCT03553875
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder, Nonverbal Learning Disability
Interventions
Memantine Hydrochloride, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
8 Years to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 2, 2026, 7:32 AM EDT
Completed Phase 3 Interventional Results available

Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases

NCT02360215
View directory record Official record
Conditions
Cognitive Impairment, Metastatic Malignant Neoplasm in the Brain, Solid Neoplasm
Interventions
Whole brain radiation therapy with hippocampal avoidance, Memantine, Whole brain radiation therapy
Radiation · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
212
States / cities
Tuscaloosa, Alabama • Gilbert, Arizona • Tucson, Arizona + 172 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 2, 2026, 7:32 AM EDT
Completed Early Phase 1 Interventional

Memantine for the Reduction of Cognitive Impairment After Radiation Therapy in Pediatric Patients With Central Nervous System Tumors

NCT04217694
View directory record Official record
Conditions
Malignant Central Nervous System Neoplasm, Primary Central Nervous System Neoplasm
Interventions
Cogstate Assessment Battery, Memantine, Memantine Hydrochloride
Behavioral · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
4 Years to 18 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 2, 2026, 7:32 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)

NCT01397422
View directory record Official record
Conditions
Dyskinesia, Levodopa Induced Dyskinesia, Parkinson's Disease
Interventions
ADS-5102 (extended release amantadine HCl)
Drug
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
33
States / cities
Sun City, Arizona • Fountain Valley, California • Long Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 2, 2026, 7:32 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI).

NCT06253923
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Amantadine Hydrochloride, Placebo
Drug
Lead sponsor
SHINKEI Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 2, 2026, 7:32 AM EDT